Home > Specialists > Medical Oncology > Dr. Xiaowei Zhang (张晓伟)
Specialty & Clinical Focus:
Medical oncology specialist at Fudan University Shanghai Cancer Center in Shanghai, with a clinical focus on systemic treatment for solid tumors, including soft-tissue and bone sarcomas, melanoma, gastrointestinal cancers, cancer of unknown primary, and multiple primary malignancies.
Professional Title & Qualifications:
Associate Chief Physician
Professor
Master's Supervisor
M.D., Ph.D. in Oncology
Hospital & Department：
Fudan University Shanghai Cancer Center – Department of Medical Oncology
(address: No. 270 Dong'an Road, Xuhui District, Shanghai, 200032)
Dr. Xiaowei Zhang (张晓伟) - Medical Oncology Specialist
Personal Biography
Dr. Xiaowei Zhang is an Associate Chief Physician, Professor, and Master’s Supervisor in medical oncology at Fudan University Shanghai Cancer Center (FUSCC). He holds a Ph.D. in Oncology from Fudan University and focuses on systemic treatment for solid tumors, particularly soft-tissue and bone sarcomas, melanoma, and gastrointestinal cancers. Dr. Zhang has participated in more than 20 global and domestic multicenter clinical studies and was a visiting scholar at MD Anderson Cancer Center in the United States, complementing his clinical experience in chemotherapy, targeted therapy, and immunotherapy.
Why Choose Dr. Xiaowei Zhang for Your Oncology Assessment?
Dr. Xiaowei Zhang is an Associate Chief Physician and Professor at Fudan University Shanghai Cancer Center, with a Ph.D. in Oncology and a focused clinical practice in the medical treatment of solid tumors. His experience is especially relevant to patients seeking expert review of soft-tissue or bone sarcoma, melanoma, gastrointestinal cancer, cancer of unknown primary, or multiple primary malignancies before deciding whether to pursue care in Shanghai.
His visiting scholar experience at MD Anderson Cancer Center and participation in more than 20 global and domestic multicenter clinical studies complement his work with chemotherapy, targeted therapy, and immunotherapy. For international patients, this combination of clinical and research experience supports a structured review of the diagnosis, prior treatment, current disease information, and key systemic-treatment questions.
Dr. Zhang also holds committee roles related to Cancer of Unknown Primary and Multiple Primary Malignant Tumors. Patients requesting a remote specialist review should prepare pathology reports, imaging, prior treatment records, and a focused question list. A well-organized case file gives the specialist a clearer basis for an oncology opinion and helps the patient decide whether an in-person pathway at FUSCC is worth pursuing.
Pre-Travel Case Review & Specialist Liaison
Before committing to medical travel to Shanghai, international patients can request MedBridgeNZ coordination for a pre-travel specialist review with Dr. Zhang. We help organize relevant pathology reports, imaging, treatment history and patient questions, coordinate translation where needed, transfer client-authorized documents, and manage appointment communication with the specialist office.
Once the specialist-review request is accepted, Dr. Zhang will review the submitted records, provide his oncology opinion, discuss potential systemic-treatment considerations, and respond to the patient’s questions. This helps patients understand whether an in-person pathway at Fudan University Shanghai Cancer Center may be worth pursuing while MedBridgeNZ prepares the practical hospital and travel logistics.
Disclaimer: MedBridgeNZ is a medical concierge provider serving a global client base. We assist with logistical coordination and facilitate access to healthcare professionals. MedBridgeNZ does not provide medical advice, diagnoses, or treatments.Any clinical feedback, treatment planning or suitability discussion remains with the relevant hospital or licensed specialist.
Secure a Remote Case Review with
Dr. Xiaowei Zhang
Areas of Expertise
Solid Tumor Therapy: Chemotherapy, targeted therapy, and immunotherapy for various solid tumors.
Soft Tissue & Bone Tumors: Soft tissue sarcoma, osteosarcoma, and Ewing sarcoma.
Skin Cancers: Malignant melanoma and other skin tumors.
Gastrointestinal Cancers: Gastric cancer, colorectal cancer (colon/rectal), esophageal cancer, and pancreatic and biliary tract tumors.
Complex Cases: Cancer of Unknown Primary (CUP), Multiple Primary Malignant Tumors (MPMT), and Head and Neck Squamous Cell Carcinoma.
Verified Client Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
* Treatment Pathway Satisfaction:
5.0/5.0
* Communication & Professionalism:
5.0/5.0
* High demand: Chosen online for specialist liaison and case reviews by over:
9,500 clients
(Source: These third-party platform indicators are provided for general reference only. They may change over time and should not be interpreted as a guarantee of diagnosis, treatment suitability, appointment availability, or individual clinical outcome.)
Work Experience
Associate Chief Physician & Professor, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Visiting Scholar, MD Anderson Cancer Center, USA (2014–2015).
Ph.D. Researcher, Fudan University (Doctorate in Oncology completed in 2009).
Education & Training
Ph.D. in Oncology, Fudan University (completed in 2009).
Visiting Scholar, MD Anderson Cancer Center, USA (2014–2015).
Awards & Honors
2014: Second Prize, Science and Technology Progress Award of the Ministry of Education (Project: Molecular mechanism of gastric cancer development and new clinical treatment strategies).
2013: Third Prize, Shanghai Medical Science and Technology Progress Award.
2012: Third Prize, China Anti-Cancer Association Science and Technology Award.
2011: First Prize, Medical Achievement Award, Fudan University Shanghai Cancer Center.
2010: Outstanding Paper Award, Fudan University Doctoral Forum (Medicine).
Academic & Professional Memberships
Standing Committee Member, Committee of Multiple Primary and Unknown Primary Tumors, China Anti-Cancer Association (CACA).
Committee Member, Melanoma Committee, China Anti-Cancer Association (CACA).
Committee Member, Cancer Nutritional Therapy Committee, Chinese Society of Clinical Oncology (CSCO).
Committee Member, Bone Metastasis Group, Sarcoma Committee, China Anti-Cancer Association (CACA).
Standing Committee Member, Precision Medicine Committee, Shanghai Biopharmaceutical Industry Association.
Standing Committee Member, Cancer Health Management and Popularization Committee, Shanghai Volunteer Association for Science and Technology.
Review Expert, National Science and Technology Expert Database (Ministry of Science and Technology).
Research & Publications
Principal Investigator: Leads two projects funded by the National Natural Science Foundation of China (NSFC).
Project Participation: Participated in over 10 national and provincial-level projects, including the Ministry of Science and Technology's "11th Five-Year" and "12th Five-Year" major research programs and the Shanghai Pujiang Talent Program.
Publications: Published 13 SCI papers as first or corresponding author in journals such as Molecular Cancer, Journal of Hematology & Oncology, Journal of Pathology, International Journal of Cancer, and JECCR. Two of these publications have an Impact Factor (IF) greater than 10.
Selected Peer-Reviewed Publications
Selected peer-reviewed publications include:
Zhang X et al. Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial. Nat Commun. 2026;17(1):6263. PMID: 42103741
Zhang X et al. Fruquintinib as first-line or second-line treatment in unresectable or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study. Clin Transl Med. 2025;15(4):e70308. PMID: 40235094
Zhang X et al. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data. Invest New Drugs. 2022;40(2):453–460. PMID: 34731354
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
Is Dr. Zhang’s expertise relevant to my specific type of cancer?
Dr. Zhang focuses on the medical treatment of solid tumors, particularly soft-tissue and bone sarcomas, melanoma, gastrointestinal cancers, Cancer of Unknown Primary, and multiple primary malignancies. MedBridgeNZ can coordinate preparation, translation where needed, and client-authorized transfer of your pathology reports, imaging, treatment history, and questions. After the review request is accepted, Dr. Zhang will examine the submitted materials and provide his specialist opinion on the case and relevant next-step considerations.
How can I request a remote specialist review with Dr. Zhang before traveling to China?
Request remote specialist-review coordination through MedBridgeNZ. We organize the case file, coordinate translation where needed, transfer authorized documents, and manage appointment communication with Dr. Zhang’s office. Once the request is accepted, Dr. Zhang will review the submitted records, provide his oncology opinion, discuss potential systemic-treatment considerations, and answer the patient’s questions. This can help you decide whether an in-person pathway in Shanghai is worth pursuing before making travel arrangements.
What can MedBridgeNZ coordinate if I pursue care at Fudan Cancer Center in Shanghai?
If Dr. Zhang’s opinion supports an in-person pathway, MedBridgeNZ can assist with appointment request coordination where available, medical invitation or visa-document coordination support, travel and accommodation planning, translation coordination, and non-clinical bilingual administrative support in Shanghai. FUSCC determines appointment timing and clinical arrangements, while MedBridgeNZ helps organize the practical steps, documentation and communication needed for the medical journey.
Flexible Ways to Connect with the Specialist
We understand that every client’s situation is unique. Beyond the Remote Written Review, we offer a range of flexible ways to access specialist insights:
-
Remote Video Liaison: For a more personal interaction, we can arrange a live video session, allowing you to discuss your case directly with the specialist with the help of our professional medical translators.
-
On-Site Proxy Liaison: If you cannot travel, our dedicated bilingual team can visit the hospital in person on your behalf. We will present your translated medical records to the specialist, facilitate your inquiries, and provide you with a comprehensive translated report of the doctor’s findings.
-
In-Person Appointment Booking: If you are planning to travel to China for treatment, we manage the complex hospital registration and appointment process, ensuring you have confirmed access to your chosen specialist upon arrival.
How MedBridgeNZ Helps You:
MedBridgeNZ is a medical concierge and logistics coordination provider for international patients seeking specialist-care pathways in China. We assist with appointment request coordination, medical-record preparation, translation coordination, client-authorized document transfer, medical invitation or visa-document coordination support, travel planning, and non-clinical bilingual administrative support. We do not provide medical advice, diagnosis, or treatment. Hospital, specialist, diagnostic, treatment, medication, travel, and other third-party charges remain separate from MedBridgeNZ coordination fees unless a specific inclusion is expressly confirmed in writing.